SAGE

Analyst Sentiment

Wall St. Consensus
Hold
27 analysts·High coverage
49
Score
1 Buy (4%)24 Hold (89%)2 Sell (7%)
Rating Breakdown
Strong Buy
00%
Buy
14%
Hold
2489%
Sell
27%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$5.00
-42.4%
Consensus
$28.00
+222.6%
Bull
$105.00
+1109.7%
12-Month Target Range27 analysts
$5.00$28.00$105.00
Current $8.68Consensus
Current Price
$8.68
Upside to Consensus
$19.32

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+36.06%
EPS
FY2028
Rev+22.13%
EPS
FY2029
Rev+17.39%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$121M$164M$201M$235M
Low$79M$164M$132M$155M
High$175M$164M$291M$342M
EBITDA Avg$-83M$-113M$-138M$-162M
Low$-121M$-113M$-200M$-235M
High$-55M$-113M$-91M$-106M
EBIT Avg$-83M$-113M$-138M$-162M
Low$-121M$-113M$-200M$-235M
High$-55M$-113M$-91M$-107M
Net Income Avg$-194M$-151M$-65M$-32M
Low$-220M$-201M$-104M$-51M
High$-125M$-35M$-36M$-18M
EPS Avg$-2.70$-1.70$-1.08$-0.53
Low$-3.61$-3.31$-1.71$-0.84
High$-2.06$-0.58$-0.60$-0.29
Analysts (Rev / EPS)11 / 811 / 104 / 55 / 4
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$30M$32M
Low$30M$32M
High$30M$32M
EBITDA Avg$-20M$-22M
Low$-20M$-22M
High$-20M$-22M
EBIT Avg$-20M$-22M
Low$-20M$-22M
High$-20M$-22M
Net Income Avg$-41M$-41M
Low$-41M$-41M
High$-41M$-41M
EPS Avg$-0.66$-0.66
Low$-0.66$-0.66
High$-0.66$-0.66
Analysts (Rev / EPS)2 / 12 / 1

Earnings Surprises

Recent Analyst Actions

Jul 7, 2025Scotiabank
Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
Target:$9.20
+0.3%from $9.17
Jun 17, 2025Truist Financial
Sage Therapeutics price target raised to $9 from $8 at Truist
Target:$9.00
-1.3%from $9.12
Jan 7, 2025RBC Capital
Sage Therapeutics price target raised to $5 from $4 at RBC Capital
Target:$5.00
-16.4%from $5.98
Nov 20, 2024RBC Capital
RBC Capital Upgrades Sage Therapeutics (SAGE) to Sector Perform
Target:$4.00
-18.5%from $4.91
Oct 30, 2024Piper Sandler
Sage Therapeutics (SAGE) PT Lowered to $26 at Piper Sandler
Target:$26.00
+229.1%from $7.90
Oct 30, 2024Scotiabank
Sage Therapeutics price target lowered to $14 from $17 at Scotiabank
Target:$14.00
+65.1%from $8.48
Oct 30, 2024Mizuho Securities
Sage Therapeutics (SAGE) PT Lowered to $10 at Mizuho
Target:$10.00
+27.3%from $7.86
Oct 30, 2024H.C. Wainwright
Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright
Target:$14.00
+65.1%from $8.48
Aug 14, 2024Truist Financial
Sage Therapeutics price target lowered to $13 from $18 at Truist
Target:$13.00
+63.5%from $7.95
Aug 6, 2024Canaccord Genuity
Sage Therapeutics price target lowered to $9 from $17 at Canaccord
Target:$9.00
+1.4%from $8.88
May 28, 2024Robert W. Baird
Sage Therapeutics initiated with a Neutral at Baird
Target:$15.00
+25.7%from $11.93
Apr 25, 2024Truist Financial
Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
Target:$18.00
+32.5%from $13.58
Apr 18, 2024Scotiabank
Sage Therapeutics (SAGE) PT Lowered to $19 at Scotiabank
Target:$19.00
+51.2%from $12.57
Apr 17, 2024Oppenheimer
Sage Therapeutics (SAGE) PT Lowered to $17 at Oppenheimer
Target:$17.00
+35.2%from $12.57
Apr 17, 2024RBC Capital
RBC Capital Issues Negative Sentiment on Sage Therapeutics (SAGE), 'we are not altogether surprised by the stock move'
Target:$26.00
+114.5%from $12.12
Apr 17, 2024Mizuho Securities
Mizuho on Sage Therapeutics (SAGE): 'management sounded very upbeat about the Zurzuvae launch, which could bode well for 1Q24 results'
Target:$20.00
+65.2%from $12.11
Apr 17, 2024Goldman Sachs
Goldman Sachs Stays Sidelined on Sage Therapeutics (SAGE) Following SAGE-178 Miss on Phase 2 Parkinson's Study
Target:$28.00
+131.2%from $12.11
Apr 17, 2024Truist Financial
Truist on Sage Therapeutics (SAGE): 'we remain on the sidelines as we see further pipeline setbacks'
Target:$22.00
+78.6%from $12.32
Dec 6, 2022J.P. Morgan
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $60
Target:$60.00
+46.4%from $40.99
Nov 11, 2022Guggenheim
Guggenheim Maintains Buy on Sage Therapeutics, Lowers Price Target to $48
Target:$48.00
+36.1%from $35.27
Jun 20, 2022Piper Sandler
SAGE Therapeutics (SAGE) Stock: $100 Target And Overweight Rating
Target:$100.00
+195.3%from $33.86
May 4, 2022RBC Capital
RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $35
Target:$35.00
+6.7%from $32.79
Feb 25, 2022BMO Capital
Sage Therapeutics (SAGE) PT Lowered to $48 at BMO Capital
Target:$48.00
+31.0%from $36.65
Feb 24, 2022RBC Capital
SAGE Therapeutics (SAGE) Gets a Hold Rating from RBC Capital
Target:$37.00
+6.6%from $34.71
Feb 24, 2022Stifel Nicolaus
Sage Therapeutics (SAGE) PT Lowered to $58 at Stifel
Target:$58.00
+67.1%from $34.71
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.